Thiophenes
Medchemexpress LLC Bisantrene dihydrochloride | 71439-68-4 | 98.9% | 471.39 g/mol | C22H24Cl2N8 | 5 MG
Bisantrene dihydrochloride is an anthracycline-class antitumor compound used in preclinical research. It intercalates into DNA, inhibits eukaryotic type II topoisomerases, and has demonstrated cytotoxic activity across multiple experimental tumor models. The material is provided as a solid for laboratory use with manufacturer storage and solubility guidance for solution preparations.
![eMolecules 1224844-66-9 | 2-Aminobenzo[d]oxazol-5-ylboronic acid pinacol ester | Combi-Blocks, Inc. | MFCD13182075 | 260.100 | C13H17BN2O3 | 98.000 | CC1(C)OB(OC1(C)C)c1ccc2oc(N)nc2c1 | 10g | 882681049](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000482466.jpg-250.jpg)
eMolecules 1224844-66-9 | 2-Aminobenzo[d]oxazol-5-ylboronic acid pinacol ester | Combi-Blocks, Inc. | MFCD13182075 | 260.100 | C13H17BN2O3 | 98.000 | CC1(C)OB(OC1(C)C)c1ccc2oc(N)nc2c1 | 10g | 882681049
2-Aminobenzo[d]oxazol-5-ylboronic acid pinacol ester | Combi-Blocks, Inc. | 1224844-66-9 | MFCD13182075 | 260.100 | C13H17BN2O3 | 98.000 | CC1(C)OB(OC1(C)C)c1ccc2oc(N)nc2c1 | 10g | 882681049
eMolecules 23680-40-2 | METHYL 3-BROMOPROPIOLATE | AstaTech | MFCD22989330 | 162.970 | C4H3BrO2 | 95.000 | COC(=O)C#CBr | 10g | 855297108
METHYL 3-BROMOPROPIOLATE | AstaTech | 23680-40-2 | MFCD22989330 | 162.970 | C4H3BrO2 | 95.000 | COC(=O)C#CBr | 10g | 855297108
eMolecules 16694-17-0 | 4-Bromo-thiophene-3-carboxylic acid | Chem-Impex | MFCD01233020 | 207.040 | C5H3BrO2S | 95.000 | OC(=O)c1cscc1Br | 1g | 112751312
4-Bromo-thiophene-3-carboxylic acid | Chem-Impex | 16694-17-0 | MFCD01233020 | 207.040 | C5H3BrO2S | 95.000 | OC(=O)c1cscc1Br | 1g | 112751312
Medchemexpress LLC 4-aminobenzo-12-crown-4 | 78554-68-4 | 98.0% | C12H17NO4 | 500 MG
4-Aminobenzo-12-crown-4 is a drug intermediate for the synthesis of various active compounds. It is supplied as a light brown to brown solid.
- Drug intermediate for synthesis
- Light brown to brown solid appearance
- Research reagent not for medical, clinical diagnostic, or food use
Apexbio Technology LLC Canertinib dihydrochloride 289499-45-2 100mg
Canertinib dihydrochloride (CAS 289499-45-2) is a small-molecule inhibitor targeting the pan-ErbB family of receptor tyrosine kinases It is designed to irreversibly inhibit ErbB receptors thereby disrupting Akt and MAPK signaling pathways Canertinib dihydrochloride exerts its biological activity primarily through irreversible binding to ErbB receptor family members In cell-based studies Canertinib dihydrochloride demonstrates apoptotic induction and reduced cell viability with an IC50 value of 3 5 nM Apoptosis induction was observed in BT474 (ErbB2-overexpressing breast cancer) and SK-N-SH (neuroblastoma) cell lines Based on these pharmacological properties Canertinib dihydrochloride holds research potential in oncology specifically for investigating ErbB signaling pathways and evaluating anti-tumor effects in cancer models
Apexbio Technology LLC Pramipexole 2HCl Monohydrate 191217-81-9 50mg
Pramipexole 2HCl Monohydrate is a synthetic non-ergoline dopamine receptor agonist targeting dopamine receptor subtypes particularly D3 D2S D2L and D4 It is designed to activate these receptors thereby modulating dopaminergic transmission pathways Pramipexole 2HCl Monohydrate exerts its biological activity primarily through selective receptor activation Based on these pharmacological properties Pramipexole 2HCl Monohydrate holds research potential in studies of receptor-ligand interactions receptor subtype functional analysis and dopamine-related neurologic or psychiatric disorders including Parkinson s disease and restless legs syndrome
Apexbio Technology LLC Ranolazine 2HCl 95635-56-6 10mg
Ranolazine 2HCl (CAS 95635-56-6) is a small molecule frequently utilized in cardiovascular research for its antianginal and antiarrhythmic activities It modulates cardiac metabolism by partially inhibiting fatty acid -oxidation thereby increasing reliance on glucose oxidation This metabolic shift is mediated through activation of pyruvate dehydrogenase in ischemic myocytes enhancing glucose utilization during myocardial ischemia Ranolazine 2HCl s ability to alter substrate preference and improve cellular energetics under hypoxic conditions supports its application in studies of cardiac ischemia arrhythmias and myocardial metabolism